NYSE:CBM - Cambrex Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$41.91 +1.25 (+3.07 %)
(As of 04/26/2019 12:21 PM ET)
Previous Close$40.66
Today's Range$40.95 - $42.06
52-Week Range$33.80 - $69.43
Volume2,019 shs
Average Volume378,805 shs
Market Capitalization$1.41 billion
P/E Ratio15.17
Dividend YieldN/A
Beta2.4
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

Receive CBM News and Ratings via Email

Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP13201110
Phone201-804-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$532.09 million
Cash Flow$4.0259 per share
Book Value$19.48 per share

Profitability

Net Income$92.41 million

Miscellaneous

Employees1,732
Market Cap$1.41 billion
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable

Cambrex (NYSE:CBM) Frequently Asked Questions

What is Cambrex's stock symbol?

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

How were Cambrex's earnings last quarter?

Cambrex Co. (NYSE:CBM) issued its quarterly earnings data on Wednesday, February, 13th. The biotechnology company reported $1.44 EPS for the quarter, beating the consensus estimate of $1.32 by $0.12. The biotechnology company earned $212.30 million during the quarter, compared to analyst estimates of $182.49 million. Cambrex had a return on equity of 14.74% and a net margin of 17.37%. The business's revenue for the quarter was up 16.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.26 EPS. View Cambrex's Earnings History.

When is Cambrex's next earnings date?

Cambrex is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Cambrex.

What guidance has Cambrex issued on next quarter's earnings?

Cambrex issued an update on its FY19 earnings guidance on Wednesday, February, 13th. The company provided EPS guidance of $1.87-2.09 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.18. Cambrex also updated its FY 2019 guidance to $1.87-2.09 EPS.

What price target have analysts set for CBM?

4 Wall Street analysts have issued 12-month price targets for Cambrex's shares. Their forecasts range from $43.00 to $63.00. On average, they expect Cambrex's stock price to reach $50.3333 in the next year. This suggests a possible upside of 19.8% from the stock's current price. View Analyst Price Targets for Cambrex.

What is the consensus analysts' recommendation for Cambrex?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 1 hold rating, 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cambrex.

Has Cambrex been receiving favorable news coverage?

News headlines about CBM stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Cambrex earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the immediate future.

Who are some of Cambrex's key competitors?

What other stocks do shareholders of Cambrex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cambrex investors own include Celgene (CELG), Illumina (ILMN), AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), CVS Health (CVS), Gilead Sciences (GILD), Juno Therapeutics (JUNO), QUALCOMM (QCOM) and Western Digital (WDC).

Who are Cambrex's key executives?

Cambrex's management team includes the folowing people:
  • Mr. Steven M. Klosk, Pres, CEO & Director (Age 62)
  • Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy and CFO (Age 53)
  • Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 53)
  • Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 41)
  • Mr. James G. Farrell, VP & Corp. Controller (Age 52)

Who are Cambrex's major shareholders?

Cambrex's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Tributary Capital Management LLC (1.07%), Summit Creek Advisors LLC (0.67%), Peregrine Capital Management LLC (0.59%), Confluence Investment Management LLC (0.32%), Scout Investments Inc. (0.26%) and CWM LLC (0.15%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex.

Which major investors are selling Cambrex stock?

CBM stock was sold by a variety of institutional investors in the last quarter, including First Quadrant L P CA, Virginia Retirement Systems ET AL, Scout Investments Inc., Peregrine Capital Management LLC and Summit Creek Advisors LLC. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Insider Buying and Selling for Cambrex.

Which major investors are buying Cambrex stock?

CBM stock was acquired by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Thompson Investment Management Inc., Confluence Investment Management LLC, CWM LLC, BNP Paribas Arbitrage SA, Nisa Investment Advisors LLC, Flagship Harbor Advisors LLC and Private Capital Group LLC. View Insider Buying and Selling for Cambrex.

How do I buy shares of Cambrex?

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cambrex's stock price today?

One share of CBM stock can currently be purchased for approximately $42.03.

How big of a company is Cambrex?

Cambrex has a market capitalization of $1.41 billion and generates $532.09 million in revenue each year. The biotechnology company earns $92.41 million in net income (profit) each year or $2.77 on an earnings per share basis. Cambrex employs 1,732 workers across the globe.

What is Cambrex's official website?

The official website for Cambrex is http://www.cambrex.com.

How can I contact Cambrex?

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]


MarketBeat Community Rating for Cambrex (NYSE CBM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  242 (Vote Outperform)
Underperform Votes:  232 (Vote Underperform)
Total Votes:  474
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel